Global Urinary Tract Infection Treatment Market is expected to grow at a CAGR of 2.41% during the forecast period from 2018-2025
A new research report published by Fior Markets with the title Global Urinary Tract Infection Treatment Market by Drug Class (Quinolones, Aminoglycosides, β-lactam, Azoles, Others), Clinical Indications, Regions, and Global Forecast 2018-2025.
As per the report, the global urinary tract infection treatment market is expected to grow from USD 10.26 Billion in 2017 to USD 12.41 Billion by 2025, at a CAGR of 2.41% during the forecast period from 2018-2025. North America emerged as the leader in the global urinary tract infection treatment market with a 36.92% share of revenue in 2017, followed by Europe. Whereas Asia Pacific region is projected to grow at the highest CAGR of 4.62% over the forecast period.
DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/386026/request-sample
Major players in the global urinary tract infection treatment market are Cipla Ltd., Johnson & Johnson, Bayer AG, Pfizer Inc., GlaxoSmithKline, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., Novartis AG AstraZeneca Plc, Dr. Reddy’s Laboratories Ltd., Sun Pharma, Merck & Co, Cubist Pharmaceuticals, Abbott Laboratories, Eli Lilly & Co., Melinta Therapeutics, Inc, Sanofi, Daiichi Sankyo, Lupin among others. Drug resistant urinary tract infection is a growing problem. Thus to overcome this problem United States Food and Drug Administration (FDA) has approved the use of the antibiotic plazomicin to treat the most complex urinary tract infections. The drug is effective against some of the hardest to treat infections including carbapenem-resistant Enterobacteriaceae.
Drug class segment is divided into quinolones, aminoglycosides, β-lactam, azoles and others. Quinolones are broad spectrum antibiotics. This particular drug type kills bacteria by stopping replication of bacterial DNA. They realize this by binding to and inhibiting the action of one of the enzymes involved in DNA replication. Thus Quinolones segment emerged as the leading segment in the global urinary tract infection treatment market with a 44.72% share of market revenue in 2017. Clinical indication is segmented in to urethritis, cystitis, pyelonephritis and others. Urethritis is the most common kind of urinary tract infection. It is most likely to be caused due to E. coli bacteria. The most common symptom is painful or difficult urination. Cystitis is the inflammation of bladder. It is most likely to be the advanced stage of urinary tract infection. Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection.
Although growing incidence of diabetes and kidney stones diseases and launch of combination treatment drugs is driving the global urinary tract infection market, lack of awareness among people pertaining UTI and side effects caused due to medications are anticipated to hinder the market growth.
About the report:
The global Urinary Tract Infection Treatment market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.
Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on firstname.lastname@example.org or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.
- CDN Newswire